Since the early days of Bavi / Sorafenib I felt it could be a big catalyst for PPHM.
We were not the first adjunct to the dance with Sorafenib.
They tried others without success. The results even for Sorafenib are modest. They know it needs a boost Bavi may have a sweet spot here.
Nice to have a BP need us as much as we need them.
Like imaging PPHM knows where are strengths are, even though these things are flying under the radar.
I know you have been a proponent of irradiation and Cotara in particular. Makes sense these treatments in particular elevate the PS giving Bavi stronger signaling to target.
Obviously we need a SOC something with a benchmark to validate Bavi's results. So until Cotara reaches that point it is off the table.
Hey, maybe we could get a Bavi/TNT trial in China where it has approval?
It would seem we are reaching a boiling point the clock is ticking toward Phase 3 NSCLC and this IST is listed as about 50% complete through phase 2 for liver cancer.
I would love to be a fly on the wall at the FDA or during a strategy session between the BOD, SK, Dr. Garnick and a few others.
Wouldn't mind a look at what's really happening at AVID either.
These are interesting times.
News 
Market Data 
Discover 
